Updated quality of life data from the phase 3b VENICE II trial: patients with relapsed or refractory chronic lymphocytic leukemia receiving venetoclax monotherapy

Affiliations

• ¹ Department of Haematology, Gold Coast University Hospital, Southport, Australia.
• ² School of Medicine, Griffiths University, Parkwood, Queensland, Australia.
• ³ Area Hematology, Hospital Italiano La Plata, Buenos Aires, Argentina.
• ⁴ Hematology Service, Hospital Universitario, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Mexico.
• ⁵ Department of Internal Medicine, Medical University Sofia, University Hospital Alexandrovska, Sofia, Bulgaria.
• ⁶ Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
• ⁷ Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary.
• ⁸ Department of Hematology, Oncology and Chemotherapy, S. P. Botkin's City Hospital, Moscow, Russia.
• ⁹ Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland.
• ¹⁰ Te Rerenga Ora Wellington Blood & Cancer Centre, Te Whatu Ora Health New Zealand Capital, Coast & Hutt Valley, Wellington, New Zealand.
• ¹¹ Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand.
• ¹² Department of Internal Medicine, Division of Haematology, National Taiwan University Hospital, Taipei City, Taiwan.
• ¹³ AbbVie, Inc., North Chicago, IL, USA.
• ¹⁴ AbbVie Schweiz AG, Cham, Switzerland.
• ¹⁵ The Clinical Haematology Department of the Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Parkville, Victoria, Australia.
• ¹⁶ Division of Blood Cells and Blood Cancer, The Walter and Eliza Hall Institute, Parkville, Victoria, Australia.